Thanks for asking, and glad to see such a good group of people following this company, and such responsive management.
Speculation is much more fun:) but I'm glad to hear "the truth" from the horse's mouth. I'm here to learn and be educated, and to share my thoughts.
IMO, downregulation versus inhibition of HDACs may be a matter of semantics, as both lead to similar end result - p53 activation at low toxicity, with good results on solid tumors. I guess I was a little confused because wikipedia lists Kevetrin as an HDAC inhibitor: